AU5416500A - Pharmaceutical composition for the treatment of calcification - Google Patents

Pharmaceutical composition for the treatment of calcification

Info

Publication number
AU5416500A
AU5416500A AU54165/00A AU5416500A AU5416500A AU 5416500 A AU5416500 A AU 5416500A AU 54165/00 A AU54165/00 A AU 54165/00A AU 5416500 A AU5416500 A AU 5416500A AU 5416500 A AU5416500 A AU 5416500A
Authority
AU
Australia
Prior art keywords
calcification
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54165/00A
Inventor
Zoltan Dardai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5416500A publication Critical patent/AU5416500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU54165/00A 1999-07-07 2000-06-02 Pharmaceutical composition for the treatment of calcification Abandoned AU5416500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9902296 1999-07-07
HU9902296A HU9902296D0 (en) 1999-07-07 1999-07-07 Pharmaceutical composition for treating caltification
PCT/HU2000/000053 WO2001003774A2 (en) 1999-07-07 2000-06-02 Pharmaceutical composition for the treatment of calcification

Publications (1)

Publication Number Publication Date
AU5416500A true AU5416500A (en) 2001-01-30

Family

ID=89998669

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54165/00A Abandoned AU5416500A (en) 1999-07-07 2000-06-02 Pharmaceutical composition for the treatment of calcification

Country Status (3)

Country Link
AU (1) AU5416500A (en)
HU (1) HU9902296D0 (en)
WO (1) WO2001003774A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227496B1 (en) * 2001-11-16 2011-07-28 Zoltan Dardai Transdermal pharmaceutical composition containing aspirine for the treatment of sclerosis
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
WO2011076401A1 (en) 2009-12-23 2011-06-30 Holger Schankin Substantially water-free pharmaceutical compositions containing acetylsalicylic acid

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE596326A (en) * 1959-11-02 1961-02-15 Guy Leopold Van Moorleghem Aspirin injectable solution and method of preparation
NL298721A (en) * 1962-10-10
FR2295753A1 (en) * 1974-12-23 1976-07-23 Despin Jean Topical acetylsalicylic acid compsns. - contg. as vehicle an inert, hydrophilic lipophilic penetrant
FR2297612A1 (en) * 1975-01-20 1976-08-13 Moorleghem Guy Van Topical analgesic aspirin compsn. - by dissolving aspirin in inert solvent and adding excipients to form ointment or liniment
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
JPS53124607A (en) * 1977-04-06 1978-10-31 Fujimoto Seiyaku Kk Novel preparation of aspirin included in dextrine analogue
FR2556218B1 (en) * 1983-12-12 1986-11-14 Gerard Alain PHARMACEUTICAL PRODUCT FOR LOCAL APPLICATION CONSTITUTED BY THE ASSOCIATION OF AN ACTIVE MEDICINAL PRINCIPLE-ENZYMATIC AGENT
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
JPS6416726A (en) * 1987-07-08 1989-01-20 Teisan Seiyaku Kk Production of aspirin dl-lysine injection
FR2648711B1 (en) * 1989-05-17 1991-10-11 Jean Blum WATER SOLUBLE COMPLEX AND STABILIZED ACETYL-SALICYLIC ACID AND MANUFACTURING METHOD THEREOF
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
AU4867799A (en) * 1998-07-09 2000-02-01 Alexander Galat Injectable sodium acetylsalicylate composition and method

Also Published As

Publication number Publication date
WO2001003774A3 (en) 2002-03-21
WO2001003774A2 (en) 2001-01-18
HU9902296D0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
AU2001272849A1 (en) Composition for the treatment of osteoarthritis
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HK1046240A1 (en) Pharmaceutical compositions for the treatment of insulin resistance
PL351134A1 (en) Compositions for treatment of disorders of the oesophagus
IL145470A0 (en) Compositions for the treatment of immune diseases
AU2935200A (en) Compounds for the treatment of obesity
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
AU6157700A (en) Malodour treatment compositions
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
AU2021601A (en) Composition for the treatment of dandruff
AU1878201A (en) Composition for the treatment of damaged tissue
AU5416500A (en) Pharmaceutical composition for the treatment of calcification
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
AU5245600A (en) Medicinal compositions for treating lower uropathy
AU2683500A (en) Compositions for the treatment of pain
HK1043938A1 (en) Composition for the treatment of psoriasis
AU1748001A (en) Pharmaceutical composition for treatment of diarrhea

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase